1;Preface;4
2;Contents;5
3;1 Principles of Medical Oncology;18
3.1;1.1 Epidemiology;18
3.2;1.2 Carcinogenesis, Molecular Tumor Biology;20
3.3;1.3 Hematopoiesis and Development of Hematological Neoplasia;24
3.4;1.4 Prevention and Screening;27
3.5;1.5 Classification of Diseases and ICD System;31
3.6;1.6 Tumor Classification and TNM System;34
3.7;1.7 Indications for Tumor Therapy;36
3.8;1.8 Performance Status of Tumor Patients ( Performance Status Scales );38
3.9;1.9 Response Evaluation in Solid Tumors;39
3.10;1.10 Common Toxicity Criteria ( NCI);42
3.11;1.11 Assessing the Quality of Life of Tumor Patients;47
3.12;1.12 Evidence- based Medicine ( EBM), Guidelines and Quality Management;49
3.13;1.13 Electronic Media;52
4;2 Special Diagnostics;56
4.1;2.1 Cytogenetics and Fluorescence In Situ Hybridization ( FISH);56
4.2;2.2 Molecular Diagnosis;59
4.3;2.3 Gene Expression Analysis using Microarrays;62
4.4;2.4 Tumor Markers;64
4.5;2.5 CD Antigens and Immunocytological Diagnosis;68
4.6;2.6 HLA System and MHC;79
5;3 Pharmacology and Pharmacotherapy;82
5.1;3.1 Basic Principles of Chemotherapy;82
5.2;3.2 Cytostatic Drugs;86
5.2.1;3.2.1 Characteristics of Clinically Used Cytostatic Drugs;88
5.2.2;3.2.2 Check List Cytostatic Treatment;148
5.2.3;3.2.3 Drug Dosage Calculation Based on Body Surface Area ( BSA);149
5.2.4;3.2.4 Dose Adjustment of Cytostatic Drugs;151
5.2.5;3.2.5 Chemotherapy During Pregnancy and Lactation;158
5.2.6;3.2.6 Selected Cytostatic Drug Incompatibilities;160
5.2.7;3.2.7 Preparation and Stability of Cytostatics;163
5.3;3.3 Hormone Therapy;170
5.3.1;3.3.1 Characterization of Hormone Treatments in Oncology;173
5.4;3.4 Cytokines;187
5.5;3.5 Monoclonal Antibodies;195
5.6;3.6 Specific Protein Kinase Inhibitors ( Targeted Therapies );205
5.7;3.7 Drug Development and Clinical Studies;215
5.8;3.8 Pharmacogenetics and Pharmacogenomics;218
6;4 Supportive Treatment;221
6.1;4.1 Antiemetic Prophylaxis and Therapy;221
6.2;4.2 Antibiotic Treatment and Neutropenic Fever;228
6.3;4.3 Growth Factors;235
6.4;4.4 Nutrition in Cancer Patients;242
6.5;4.5 Pain Control;252
6.6;4.6 Fatigue;258
6.7;4.7 Bisphosphonates;260
6.8;4.8 Malignant Effusions;266
6.8.1;4.8.1 Malignant Pleural Effusion;267
6.8.2;4.8.2 Malignant Pericardial Effusion;271
6.8.3;4.8.3 Malignant Ascites;274
6.9;4.9 Transfusion Therapy;278
6.10;4.10 Human Sperm Cryopreservation;288
6.11;4.11 Cryopreservation of Human Pronuclear Oocytes;291
6.12;4.12 Sexual Dysfunction;293
6.13;4.13 Physiotherapy and Sports Medicine;295
6.14;4.14 Principles of Oncology Nursing Care;298
6.15;4.15 Psycho- oncological Care;303
6.16;4.16 Rehabilitation;306
7;5 Particular Treatment Procedures;310
7.1;5.1 Hematopoetic Stem Cell Technology ( Harvesting, Culture, Purging);310
7.2;5.2 Autologous Hematopoetic Stem Cell Transplantation;313
7.3;5.3 Allogeneic Hematopoetic Stem Cell Transplantation;319
7.4;5.4 Granulocyte Transfusion;326
7.5;5.5 Immunotherapy;328
7.6;5.6 Gene Therapy;332
7.7;5.7 Inhibition of Angiogenesis;336
7.8;5.8 Developmental Therapeutics;339
8;6 Hematology and Hemostasis;344
8.1;6.1 Aplastic Anemia;344
8.2;6.2 Neutropenia and Agranulocytosis;349
8.3;6.3 Thrombocytopenia;353
8.3.1;6.3.1 Immune ( Idiopathic) Thrombocytopenic Purpura ( ITP, Werlhof s Disease);356
8.3.2;6.3.2 Heparin- induced Thrombocytopenia ( HIT);360
8.3.3;6.3.3 Thrombotic Microangiopathies ( TTP- HUS);362
8.4;6.4 Anemia;365
8.4.1;6.4.1 Hypochromic Anemia;368
8.4.2;6.4.2 Megaloblastic Anemia;372
8.4.3;6.4.3 Hemolytic Anemia;376
8.4.4;6.4.4 Normochromic Anemia;386
8.5;6.5 Coagulation Disorders;388
8.5.1;6.5.1 Acquired Coagulation Disorders;393
8.5.2;6.5.2 Factor VIII Deficiency ( Hemophilia A);398
8.5.3;6.5.3 Factor IX Deficiency ( Hemophilia B);401
8.5.4;6.5.4 Von Willebrand s Disease ( VWD);403
8.5.5;6.5.5 Disseminated Intravascular Coagulation ( DIC);406
8.6;6.6 Thromboembolism and Thrombophilia;410
9;7 Hematological Neoplasia;417
9.